H.C. Wainwright Raises Palvella Therapeutics Price Target to $270

H.C. Wainwright has increased its price target for Palvella Therapeutics to $270 per share. This adjustment reflects a change in the expected value of the company, which could influence investor sentiment and trading behavior. The updated target suggests a new valuation based on current market conditions, which may impact the stock's performance. The previous target was not specified.

Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.